Lunesta and Acetaminophen Interaction: What You Need to Know

Updated Jan 28, 2025

Image: HealthRX.com clinical image

At a glance

Interaction severity / low at standard doses; neither FDA label lists the other drug as contraindicated
Primary concern / additive CNS depression and shared hepatic metabolic load, not a direct pharmacokinetic conflict
Hepatic overlap / both drugs are cleared partly through the liver; liver disease raises the stakes for both
Eszopiclone metabolism / CYP3A4 is the primary pathway, with a minor role for CYP2E1
Acetaminophen metabolism / mostly glucuronidation and sulfation, with a smaller fraction going through CYP2E1/CYP3A4 to the reactive metabolite NAPQI
Acetaminophen ceiling / commonly cited as 3,000 to 4,000 mg/day for healthy adults, lower (around 2,000 mg/day) with liver risk factors
Alcohol warning / a separate, well-established FDA black-box warning for eszopiclone; alcohol also raises NAPQI formation from acetaminophen
Monitoring / liver function testing is reasonable for chronic combined use or in at-risk patients, not for occasional short-term use
Recommended action / use the lowest effective dose of each drug; there is no established need to separate the timing of doses
Always disclose / tell your prescriber and pharmacist about every OTC analgesic you take alongside a sleep medication

Are Lunesta and Acetaminophen Safe to Take Together?

For most healthy adults, yes. Standard over-the-counter acetaminophen doses (325 to 650 mg every 4 to 6 hours, staying under the recommended daily ceiling) do not produce a clinically established pharmacokinetic conflict with eszopiclone 1 to 3 mg at bedtime. The FDA label for eszopiclone does not name acetaminophen as a contraindication or flag it in the drug interactions section, and acetaminophen's own labeling does not name eszopiclone.

Both drugs place some load on the liver, and both can contribute to CNS depression in susceptible people. The picture changes if acetaminophen use is chronic, if intake exceeds the recommended ceiling, or if the patient has underlying liver disease, heavy alcohol use, or malnutrition.

Why Clinicians Still Pay Attention to This Combination

Neither drug is entirely without risk on its own. Eszopiclone carries an FDA boxed warning for complex sleep behaviors (such as sleepwalking or sleep-driving with no memory of the event) and for next-morning impairment [1]. Acetaminophen overdose, often unintentional and often from combination products, is a leading cause of acute liver failure in the United States [2]. Combining the two drugs at standard doses does not simply add these risks together, but the shared hepatic burden is the reason clinicians ask about both.

What the FDA Labels Actually Say

The eszopiclone prescribing information states that drugs that inhibit CYP3A4 "may increase eszopiclone plasma concentration," and separately warns that concomitant use with other CNS depressants "may produce additive CNS depression" [1]. Acetaminophen at standard doses is not considered a meaningful CYP3A4 inhibitor, so the first warning does not apply to this pairing. The additive CNS depression warning is the one with any relevance here, and even that is based on eszopiclone's general class warning rather than a study of this specific combination.

Mechanism: How Each Drug Is Metabolized

Eszopiclone and CYP3A4

Eszopiclone is the S-enantiomer of zopiclone. It is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2E1, producing the metabolites (S)-zopiclone-N-oxide and (S)-N-desmethylzopiclone [1]. Its half-life is roughly 6 hours in healthy adults and extends to roughly 9 hours in older adults. Eszopiclone itself does not meaningfully inhibit or induce CYP3A4 at therapeutic doses.

Because eszopiclone depends heavily on CYP3A4, strong inhibitors of that enzyme (ketoconazole, ritonavir, clarithromycin) can raise eszopiclone exposure substantially, per the FDA label's interaction data [1]. Acetaminophen at standard doses does not produce this effect, since it is not a clinically meaningful CYP3A4 inhibitor.

Acetaminophen and the NAPQI Pathway

Acetaminophen is cleared through three main hepatic routes: glucuronidation and sulfation handle most of a standard dose, and a smaller fraction is processed by cytochrome P450 enzymes, mainly CYP2E1 and to a lesser degree CYP3A4, into the reactive metabolite NAPQI [3]. Under normal conditions, hepatic glutathione neutralizes NAPQI quickly. When acetaminophen intake is excessive, or when CYP2E1 is induced by chronic alcohol use, fasting, or certain drugs, NAPQI can accumulate faster than glutathione can clear it, and that is what drives acetaminophen-related liver injury [3].

Eszopiclone's minor CYP2E1 role and acetaminophen's minor CYP2E1/CYP3A4 role overlap mechanistically. This overlap is the pharmacologic basis for a theoretical interaction at the enzyme level. Whether that overlap produces any clinically measurable effect at standard doses of either drug has not been established in a dedicated interaction study; it is a plausible mechanism, not a demonstrated clinical finding.

Where CNS Depression Enters the Picture

Eszopiclone acts at GABA-A receptors, enhancing chloride channel conductance and producing dose-dependent sedation [1]. Acetaminophen has a weak central analgesic effect, thought to involve descending serotonergic pathways and the endocannabinoid system [4], but this is not a sedative mechanism in the way eszopiclone's GABA-A activity is. Whether acetaminophen's central activity meaningfully adds to eszopiclone's sedation at standard doses has not been directly studied. The clearer, better-supported risk is next-morning impairment from eszopiclone itself, which is worsened by any other CNS depressant taken the same evening, alcohol most of all.

Evidence-Status Interaction Assessment

The table below separates what is directly supported by the sources cited in this article, what is pharmacologically plausible but unproven, and what remains unestablished. Use it as a starting point for a pharmacist or clinician conversation, not as a substitute for one.

Claim	Evidence status	Basis	What still needs verification
Eszopiclone is metabolized primarily by CYP3A4, with a minor CYP2E1 role	Established	FDA eszopiclone label, clinical pharmacology section [1]	None for this specific point
Acetaminophen at standard doses is not a clinically meaningful CYP3A4 inhibitor	Established	FDA drug interaction substrate/inhibitor reference table FDA table	Confirm the current version of the FDA table before relying on it for a specific patient
Acetaminophen is metabolized in part through CYP2E1 to the reactive metabolite NAPQI	Established	Heard KJ, NEJM review of acetaminophen poisoning mechanism [3]	None for this specific point
The CYP2E1/CYP3A4 overlap between the two drugs could theoretically change either drug's clearance	Pharmacologically plausible, not clinically demonstrated	Inferred from each drug's individual metabolic pathway; no dedicated pharmacokinetic interaction study of the pair was located	A formal PK interaction study of eszopiclone plus acetaminophen has not been identified; do not assume a specific magnitude of effect
Strong CNS depressants combined with eszopiclone raise sedation and impairment risk	Established as a class warning	FDA eszopiclone boxed warning and label language [1]	Acetaminophen's own contribution to this effect at standard doses is not separately quantified in the label
Standard-dose acetaminophen combined with eszopiclone raises hepatotoxicity risk above either drug alone in a person with normal liver function	Not established	No case series or interaction study of this specific pairing was located among the sources reviewed	A pharmacist should check current interaction-checker databases and product labeling directly, and this should be reconfirmed if new safety data emerge
Chronic combined use in a patient with hepatic impairment carries added risk relative to either drug alone	Plausible, extrapolated from general hepatic dosing principles	FDA label hepatic-impairment dosing guidance for eszopiclone [1]; general pharmacology of reduced clearance in liver disease	Confirm current hepatic dosing recommendations with the label or a pharmacist before dosing a patient with known liver disease

Risk by Patient Profile

Interaction-checker tools generally do not flag standard-dose acetaminophen as a labeled interaction with eszopiclone, which is consistent with neither FDA label naming the other drug. That said, risk is not uniform across patients. The table below organizes the clinical picture by population, based on the individual risk factors described in each drug's own labeling and the general hepatology principles above rather than on a study of the combination itself.

Patient Profile	Estimated Risk Level	Primary Concern
Healthy adult, standard doses	Low	Next-morning sedation from eszopiclone itself
Older adults (65 and up)	Low to moderate	Longer eszopiclone half-life, fall risk
Chronic heavy alcohol use	Moderate to high	CYP2E1 induction, reduced glutathione reserve, additive sedation
Hepatic impairment (Child-Pugh B or C)	High	Reduced clearance of both drugs
Chronic acetaminophen use above the recommended ceiling	Moderate	Cumulative hepatic load
Concurrent opioid use	High	This is a separate, better-documented risk: combined CNS and respiratory depression

Hepatotoxicity: What the Data Actually Show

Acetaminophen and Acute Liver Failure

A prospective multicenter study by Larson and colleagues, published in Hepatology, followed 662 patients with acute liver failure across 22 U.S. centers. Acetaminophen was identified as the cause in 46% of cases, and unintentional overdose, often from combination products, accounted for a large share of those [2]. This matters here because a patient taking a prescription sleep aid at night may not realize that a daytime pain reliever, cold medicine, or opioid-combination product also contains acetaminophen, pushing total daily intake above the recommended ceiling without anyone intending it.

Eszopiclone's Hepatic Profile

Eszopiclone carries a low, mostly post-marketing signal for liver enzyme elevation. The FDA label notes rare reports of elevated ALT and AST and instructs caution with a lower starting dose in patients with severe hepatic impairment [1]. Liver function abnormalities were not identified as a major safety finding in the trials that supported FDA approval.

The Alcohol Multiplier

Both risks increase sharply when alcohol enters the picture. Alcohol induces CYP2E1, which speeds NAPQI formation from acetaminophen, and it also adds directly to eszopiclone's sedative effect. The FDA boxed warning for eszopiclone explicitly names alcohol as a dangerous combination on its own, independent of acetaminophen [1]. A patient who drinks and takes both drugs the same evening is combining three separate pressures: faster NAPQI generation, reduced glutathione reserve from chronic drinking, and additive sedation.

Monitoring Parameters

When Liver Function Testing Makes Sense

Routine liver function testing is not necessary for a healthy adult using both drugs short-term at standard doses. It becomes reasonable in these situations:

Chronic combined use, roughly more than 2 to 3 weeks of daily acetaminophen alongside nightly eszopiclone
Pre-existing liver disease, even mild (fatty liver, hepatitis C, alcohol use disorder)
Total acetaminophen intake regularly above 2,000 mg/day
New symptoms such as right upper quadrant pain, jaundice, dark urine, or unexplained fatigue

A baseline metabolic panel before starting eszopiclone in a patient who already uses daily acetaminophen for chronic pain is reasonable clinical practice, with a repeat at around 3 months if both are continued.

Sedation and Next-Morning Impairment

The more immediately relevant monitoring target for most patients is next-morning impairment from eszopiclone itself. A meta-analysis of on-road driving studies of hypnotic drugs found measurable residual psychomotor and driving impairment with some agents in this class [5]. That analysis was not specific to the eszopiclone-acetaminophen combination, and the exact duration of impairment varies by dose, drug, and individual, so treat any specific hour figure with caution and verify against the primary literature before using it in patient counseling. The practical takeaway is that clinicians should ask patients specifically about morning grogginess, difficulty concentrating, or memory lapses, and should not assume acetaminophen makes this better or meaningfully worse without direct evidence either way.

Dose Adjustment Guidance

Eszopiclone

No formal dose adjustment of eszopiclone is required specifically because of acetaminophen co-administration in a patient with normal liver function. In patients with hepatic impairment, the FDA label recommends starting at a lower dose [1]. If a patient with hepatic impairment also needs regular acetaminophen, the lowest effective dose of both drugs, with close monitoring, is the safest approach.

Acetaminophen

General guidance from FDA labeling and liver health organizations:

Healthy adults: commonly cited ceilings range up to 4,000 mg/day, with many clinicians using 3,000 mg/day as a practical working limit
Adults with liver disease, chronic heavy alcohol use, or malnutrition: closer to 2,000 mg/day
Children: weight-based dosing per the product label; never use adult formulations

Patients taking eszopiclone who also use combination cold, flu, or opioid-combination products need to account for the acetaminophen already in those products toward their daily total. This is the most common source of unintentional excess.

Patient Counseling Points

These are the practical talking points that matter most when a patient is starting eszopiclone and also uses acetaminophen regularly, in order of clinical priority.

Add up your total daily acetaminophen across every product, brand name or generic, prescription or OTC, before taking a bedtime eszopiclone dose. Stay under the ceiling your prescriber recommends, lower if you drink alcohol or have any liver condition.
Do not drink alcohol on nights you take eszopiclone. This is its own FDA boxed warning, independent of acetaminophen [1], and it also raises NAPQI production from any acetaminophen on board.
Do not drive or operate machinery for at least 8 hours after taking eszopiclone. This window is longer if you drink alcohol, take opioids, or use other sedating medications the same evening.
Report new liver symptoms promptly. Right-sided abdominal pain, yellowing of the eyes or skin, unusually dark urine, or persistent fatigue warrant stopping acetaminophen and calling your provider.
Tell every provider and pharmacist about all your medications. Combination products are the most common source of accidental acetaminophen excess, and a pharmacist can screen your full medication list for hidden acetaminophen quickly.

Special Populations

Older Adults

Adults 65 and older already have a lower recommended eszopiclone starting dose based on pharmacokinetic data showing a longer half-life in this group [1]. Falls are a documented concern with nonbenzodiazepine hypnotics in older adults, and the American Geriatrics Society's 2023 Beers Criteria update flags this drug class as one to approach cautiously in this population because of fall and cognitive risk [6]. If an older patient also takes acetaminophen at night for arthritis pain, the added sedation risk, while modest, is the practical concern. Taking acetaminophen earlier in the evening rather than right at bedtime may reduce the overlap in peak CNS effects, though this specific strategy has not been formally studied for this drug pair.

Patients on Long-Term Acetaminophen for Chronic Pain

Patients managing osteoarthritis or low back pain on regular acetaminophen need careful dose accounting. The 2019 ACR/Arthritis Foundation guideline continues to list acetaminophen as a conditional recommendation for knee and hip osteoarthritis, acknowledging its modest effect size against the GI safety tradeoffs of NSAIDs [7]. If a patient in this category also takes eszopiclone nightly, total daily acetaminophen intake is worth reviewing at every refill.

Pediatric Patients

Eszopiclone is not FDA-approved for patients under 18. A pediatric trial in children and adolescents did not demonstrate improvement over placebo and was associated with more adverse events, which is part of why the FDA has not approved this indication [1]. This population is outside the scope of the adult dosing discussion above, and this article does not address pediatric use.

What the FDA Label Says Directly

Rather than relying on a secondhand summary, the eszopiclone label itself states: "The use of eszopiclone with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression" [1]. Acetaminophen sits at the mild end of that spectrum since it is not itself a classic CNS depressant, but the general principle, that combining sedating substances compounds risk, still applies as a reason for caution rather than alarm.

Comparing Eszopiclone Interactions: Where Acetaminophen Sits

This comparison is a general characterization based on known CYP3A4 pharmacology and the FDA label where cited. Not every row reflects a dedicated interaction study of eszopiclone specifically; several are extrapolated from how strongly a drug affects CYP3A4 or adds to CNS depression as a class.

Co-administered Drug	Interaction Severity	Mechanism
Ketoconazole 400 mg	High, substantially raises eszopiclone exposure	Strong CYP3A4 inhibition, per FDA label data [1]
Rifampicin	High, likely reduces eszopiclone efficacy	Strong CYP3A4 induction (based on general CYP3A4 pharmacology, not a dedicated eszopiclone study)
Alcohol	High, CNS depression plus hepatotoxicity risk	Additive sedation, CYP2E1 induction; explicit FDA boxed warning [1]
Opioids	High, respiratory depression risk	Additive CNS and respiratory depression
Benzodiazepines	Moderate to high, additive CNS depression	Additive sedation
Acetaminophen, standard doses	Low, no labeled interaction	Minor CYP2E1/3A4 overlap, weak central analgesic activity
Ibuprofen, standard doses	Low	Minimal shared metabolic pathways

Acetaminophen at recommended doses sits toward the safer end of this spectrum. The higher-severity interactions involve strong CYP3A4 modulators or drugs that are themselves classic CNS or respiratory depressants.

Practical Takeaways for Clinicians

Document total daily acetaminophen intake at each visit, prescription and OTC combined
Consider baseline and 3-month liver function testing for patients using both drugs chronically
Counsel on alcohol avoidance explicitly rather than generally, given the separate boxed warning
Review combination products for hidden acetaminophen content
Use the lowest effective eszopiclone dose
Consider cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment; the 2016 American College of Physicians guideline recommends that all adult patients receive CBT-I as initial treatment for chronic insomnia disorder before pharmacotherapy [8]

For patients who still need medication after CBT-I, the lowest effective dose for the shortest necessary duration remains standard practice.

Frequently asked questions

Can I take Lunesta with acetaminophen?

For most healthy adults taking standard acetaminophen doses (325 to 650 mg per dose, staying under the daily ceiling), combining it with Lunesta (eszopiclone 1 to 3 mg) is considered low risk. Neither drug's FDA label lists the other as contraindicated. Tell your prescriber and pharmacist about all medications you take, including OTC products.

Is it safe to combine Lunesta and acetaminophen?

Generally yes at recommended doses in healthy adults without liver disease. The main precautions are staying under your recommended acetaminophen ceiling, avoiding alcohol the same evening, and not driving for at least 8 hours after taking eszopiclone. Patients with liver impairment should discuss dosing with their physician before using both together.

Does acetaminophen affect how Lunesta works in the body?

Acetaminophen at standard doses does not meaningfully inhibit CYP3A4, the enzyme mainly responsible for breaking down eszopiclone, so it is unlikely to raise eszopiclone blood levels in a clinically meaningful way. Both drugs have a minor overlap at CYP2E1, but whether this changes eszopiclone levels at standard acetaminophen doses has not been directly studied.

Can Lunesta and acetaminophen together damage the liver?

At recommended doses in a person with normal liver function, this specific combination has not been shown to carry added liver damage risk beyond each drug's individual profile, and no dedicated interaction study of the pair was identified for this article. Acetaminophen overdose is a leading cause of acute liver failure in the U.S., and eszopiclone has rare post-marketing reports of liver enzyme elevation. Patients with liver disease, malnutrition, or chronic heavy alcohol use should use the lowest effective doses and consider liver function monitoring, and should confirm current guidance with their prescriber or pharmacist.

What are the most dangerous Lunesta drug interactions?

The higher-severity interactions involve strong CYP3A4 inhibitors like ketoconazole, alcohol, opioids, and other CNS depressants such as benzodiazepines and tricyclic antidepressants. Acetaminophen at standard doses does not rank among these.

Should I take Lunesta and acetaminophen at the same time?

There is no established pharmacological reason you must separate the timing of these two drugs in a healthy adult. Some clinicians suggest taking acetaminophen a bit earlier in the evening rather than at the same moment as eszopiclone to reduce overlap in CNS effects, but this is a practical suggestion rather than a studied requirement.

Does Lunesta interact with Tylenol Extra Strength?

Tylenol Extra Strength contains 500 mg of acetaminophen per tablet. At typical doses taken at bedtime alongside eszopiclone, the interaction risk is still considered low in healthy adults. The concern arises if you also take other acetaminophen-containing products during the day and approach or exceed your daily ceiling. Check every OTC product label for acetaminophen content.

Can older adults take both Lunesta and acetaminophen?

Adults 65 and older are already advised to start eszopiclone at a lower dose due to a longer half-life in this group. Acetaminophen is often preferred over NSAIDs for pain in older adults, so this combination is common in practice. Fall risk from sedation is the main practical concern. Scheduling acetaminophen earlier in the evening and using the lowest effective eszopiclone dose can help reduce this risk.

What happens if I accidentally take too much acetaminophen while on Lunesta?

If you believe you have taken more than the recommended daily maximum of acetaminophen, contact Poison Control (1-800-222-1222 in the U.S.) immediately. Treatment with N-acetylcysteine is most effective when started early after an overdose. Do not wait for symptoms; acetaminophen-related liver injury often has a silent window before clinical signs appear.

Is there a safer sleep aid than Lunesta for people who use acetaminophen daily?

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment recommended by the American College of Physicians before any sleep medication [8]. For patients who need pharmacotherapy and also take daily acetaminophen, eszopiclone's interaction profile is not uniquely problematic based on the evidence reviewed here. Other options, such as low-dose doxepin or melatonin receptor agonists, have different metabolic profiles. Discuss alternatives with your prescriber based on your full medical history.

Does Lunesta affect how well acetaminophen relieves pain?

No study identified for this article has demonstrated that eszopiclone alters acetaminophen's pain-relieving effect. The two drugs work through distinct mechanisms, and eszopiclone does not inhibit or induce the pathways most relevant to acetaminophen's analgesic activity.

References

U.S. Food and Drug Administration. Lunesta (eszopiclone) Prescribing Information. Revised 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf
Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364-1372. https://pubmed.ncbi.nlm.nih.gov/16317692/
Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285-292. https://www.nejm.org/doi/full/10.1056/NEJMct0708210
Mallet C, Daulhac L, Bonnefont J, et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain. 2008;139(1):190-200. https://pubmed.ncbi.nlm.nih.gov/18485596/
Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf. 2006;1(1):63-71. https://pubmed.ncbi.nlm.nih.gov/18690919/
American Geriatrics Society 2023 updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052-2081. https://pubmed.ncbi.nlm.nih.gov/37139824/
Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220-233. https://pubmed.ncbi.nlm.nih.gov/31908163/
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. https://www.annals.org/aim/fullarticle/2532872

Summary of what I changed for the editorial handoff: removed the fabricated "Pharmacists' Society of the Pacific Coast" quotation (no source existed for it), fixed a citation mismatch where the text cited a nonexistent "2012 Journal of Clinical Sleep Medicine" study but the reference list actually pointed to the 2006 Verster driving-safety meta-analysis, softened the unsourced "Lexicomp/Micromedex/Drugs.com" specific severity ratings, dropped an unverifiable exact pediatric trial N-count, paraphrased the Beers Criteria characterization instead of quoting it verbatim, and added the directed evidence-status artifact (marked ``) distinguishing established, plausible, and unestablished claims about this specific interaction.